Clinical Research Directory

Inclusion Criteria: * Age ≥ 18 years, gender not specified. * Newly diagnosed patients with diffuse large B-cell lymphoma (DLBCL) confirmed by histopathological examination. Patients should test positive for plasma cfDNA before treatment (defined as positive for point mutations, CNV, IgH-related fusion, or IG clonal rearrangement) and achieve complete metabolic remission after 6 cycles of R-CHOP chemotherapy (evaluated by Lugano response assessment criteria). * Patients for whom the researcher predicts a life expectancy of \>6 months. * Signed informed consent form. Exclusion Criteria: * Patients who have undergone autologous stem cell transplantation. * Patients with a history of other malignant tumors, except for basal cell carcinoma of the skin or in situ cervical cancer. * Patients with uncontrolled cardiovascular diseases, coagulation disorders, connective tissue diseases, severe infectious diseases, and other such conditions; * Primary central nervous system lymphoma. * Patients with mental illness or others known or suspected to be unable to fully comply with the study protocol. * Pregnant or lactating women. * HbsAg-positive patients who need to undergo HBV-DNA testing and can only be included if they seroconvert. Additionally, if the HbsAg test is negative but the HBcAb test is positive (regardless of HbsAb status), HBV-DNA testing is also required. If the result is positive, inclusion is possible only after seroconversion. * HIV-infected individuals. * Other concurrent and uncontrolled diseases that researchers believe may affect the medical condition of patients participating in the study.